Skip to main content

Table 1 Patient and transplant characteristics

From: Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

Patient characteristics Sorafenib group (n=100) Control group (n=102) P value
Gender, male/female 50 (50.0%)/50 (50.0%) 52 (51.0%)/50 (49.0%) 0.889
Patient age, median (range), years 35 (18–60) 35 (18–59) 0.916
WBC at diagnosis, median (range) 54.8 (1.3–463.0) 74.8 (1.7–385.1) 0.473
Cytogenetic risk#    0.818
Low risk 6 (6.0%) 4 (3.9%)  
Intermediate risk 80 (80.0%) 85 (83.3%)  
High risk 7 (7.0%) 5 (4.9%)  
Unknown 7 (7.0%) 8 (7.8%)  
NPM1 mutation    0.575
Concomitant 29 (29.0%) 26 (25.5%)  
Without 71 (71.0%) 76 (74.5%)  
EBV serostatus    0.910
D−/R- 21 (21.0%) 19 (18.6%)  
D+/R- 24 (24.0%) 28 (27.5%)  
D−/R+ 20 (20.0%) 22 (21.6%)  
D+/R+ 35 (35.0%) 33 (32.3%)  
CMV serostatus    0.982
D−/R− 7 (7.0%) 7 (6.9%)  
D+/R− 5 (5.0%) 4 (3.9%)  
D−R+ 9 (9.0%) 10 (9.8%)  
D+/R+ 79 (79.0%) 81 (79.4%)  
Sorafenib pre-transplant    0.654
Use 59 (59.0%) 57 (55.9%)  
No use 41 (41.0%) 45 (44.1%)  
CR status at transplant    0.546
≥ CR2 21 (21.0%) 18 (17.6%)  
CR1 79 (79.0%) 84 (82.4%)  
MRD at transplant    0.723
Positive 31 (31.0%) 34 (33.3%)  
Negative 69 (69.0%) 68 (66.7%)  
GVHD prophylaxis    0.512
CsA+MTX+MMF 44 (44.0%) 39 (38.2%)  
CsA+MTX+ATG 8 (8.0%) 6 (5.9%)  
CsA+MTX+ATG+MMF 48 (48.0%) 57 (55.9%)  
ATG use in the conditioning    0.405
Use 44 (44.0%) 39 (38.2%)  
No use 56 (56.0%) 63 (61.8%)  
Transplant modality    0.512
MSD 44 (44.0%) 39 (38.2%)  
MUD 8 (8.0%) 6 (5.9%)  
HID 48 (48.0%) 57 (55.9%)  
Donor sources    0.262
PBSC 52 (52.0%) 45 (44.1%)  
PBSC+BM 48 (48.0%) 57 (55.9%)  
Median CD34+cells per graft, 106/kg (range) 6.3 (3.7–10.2) 6.1 (3.3–11.3) 0.746
  1. Abbreviations: WBC white blood cell, NPM1 nucleophosmin1, EBV Epstein-Barr virus, D donor, R recipient, CMV cytomegalovirus, CR complete remission, CR2 second complete remission, CR1 first complete remission, MRD minimal residual disease, GVHD graft-versus-host disease, CsA cyclosporine A, MTX methotrexate, MMF mycophenolate, ATG antithymocyte immunoglobulin, MSD HLA-matched sibling donor, MUD HLA-matched unrelated donor, HID haploidentical donor, PBSC peripheral blood stem cell, BM bone marrow. # Cytogenetic risk was determined according to ELN 2010 criteria